Kenvue (NYSE:KVUE) Stock Sold Rep. Kevin Hern

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Kenvue Inc. (NYSE:KVUE). In a filing disclosed on August 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Kenvue stock on August 5th. The trade occurred in the Representative’s “HERN FAMILY FOUNDATION” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Diageo (NYSE:DEO) on 8/5/2026.
• Sold $1,001 – $15,000 in shares of Estee Lauder Companies (NYSE:EL) on 8/5/2026.
• Sold $1,001 – $15,000 in shares of Organon & Co. (NYSE:OGN) on 8/5/2026.
• Sold $1,001 – $15,000 in shares of Mondelez International (NASDAQ:MDLZ) on 8/5/2026.
• Sold $1,001 – $15,000 in shares of Versant (NASDAQ:VSNT) on 8/5/2026.
• Sold $1,001 – $15,000 in shares of Comcast (NASDAQ:CMCSA) on 8/5/2026.

Kenvue Stock Up 0.3%

KVUE opened at $19.09 on Wednesday. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $21.95. The firm has a market capitalization of $36.66 billion, a P/E ratio of 21.94, a PEG ratio of 1.36 and a beta of 0.47. The company’s 50-day moving average is $18.83 and its 200 day moving average is $18.12. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.01 and a quick ratio of 0.71.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The firm had revenue of $3.96 billion during the quarter, compared to the consensus estimate of $3.97 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.29 earnings per share. Research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, August 26th. Stockholders of record on Wednesday, August 12th will be issued a $0.21 dividend. This is an increase from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.84 annualized dividend and a dividend yield of 4.4%. The ex-dividend date is Wednesday, August 12th. Kenvue’s dividend payout ratio is currently 95.40%.

Institutional Trading of Kenvue

Institutional investors have recently modified their holdings of the business. CoreCap Advisors LLC raised its stake in shares of Kenvue by 64.9% during the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after purchasing an additional 591 shares in the last quarter. Montag A & Associates Inc. grew its stake in shares of Kenvue by 6.3% in the 1st quarter. Montag A & Associates Inc. now owns 10,156 shares of the company’s stock valued at $175,000 after buying an additional 600 shares in the last quarter. Cornerstone Wealth Group LLC increased its holdings in Kenvue by 5.9% in the first quarter. Cornerstone Wealth Group LLC now owns 10,810 shares of the company’s stock worth $187,000 after buying an additional 606 shares during the last quarter. Physician Wealth Advisors Inc. increased its holdings in Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after buying an additional 618 shares during the last quarter. Finally, Mill Creek Capital Advisors LLC raised its position in Kenvue by 0.6% during the fourth quarter. Mill Creek Capital Advisors LLC now owns 124,213 shares of the company’s stock valued at $2,143,000 after acquiring an additional 701 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on KVUE shares. Weiss Ratings raised Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, June 15th. Citigroup lowered their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 15th. Zacks Research downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Barclays increased their price target on shares of Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 21st. Finally, Wall Street Zen lowered shares of Kenvue from a “buy” rating to a “hold” rating in a research report on Saturday. Three investment analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $19.27.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.